Skip to main content

Table 6 ACR50 and mPsARC response rates at week 12 in patients with PsA stratified by prior anti-TNF therapy

From: Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy

  ACR50 mPsARC
  Response rate, Unadjusted odds ratio Pvalue Response rate, Unadjusted odds ratio Pvalue
  n/N (%) (95% CI)   n/N (%) (95% CI)  
History of prior anti-TNF therapy       
   Prior ETN or IFX or both 25/60 (41.7) 0.65 (0.37 to 1.13) 0.130 42/59 (71.2) 0.66 (0.36 to 1.23) 0.194
   No prior ETN/IFXa 182/348 (52.3)    272/345 (78.8)   
  1. aUsed as reference value. ACR50, American College of Rheumatology 50% or more improvement; CI, confidence interval; ETN, etanercept; IFX, infliximab; mPsARC, modified Psoriatic Arthritis Response Criteria; PsA, psoriatic arthritis.